---
title: "Damora Therapeutics grants 451,000 inducement stock options at $28.99 per share"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294730834.md"
description: "Damora Therapeutics granted 451,000 inducement stock options to six newly hired non-executive employees on August 1, 2026. The options have a $28.99 exercise price and a 10-year term. Vesting begins with 25% on the first anniversary of employment, followed by monthly installments over 36 months. These awards were issued under the company’s 2022 Inducement Plan."
datetime: "2026-08-03T20:01:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294730834.md)
  - [en](https://longbridge.com/en/news/294730834.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294730834.md)
---

# Damora Therapeutics grants 451,000 inducement stock options at $28.99 per share

-   Damora Therapeutics granted inducement stock options covering 451,000 ordinary shares to six newly hired, non-executive employees on Aug. 1, 2026. \* Options carry a 10-year term with an exercise price of USD 28.99 per share. \* Vesting starts with 25% on the first anniversary of each employee’s start date, then monthly installments over the next 36 months. \* Awards were issued under the company’s 2022 Inducement Plan with terms set in individual option award agreements. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608031601PRIMZONEFULLFEED9802688) on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [DMRA.US](https://longbridge.com/en/quote/DMRA.US.md)

## Related News & Research

- [Damora Therapeutics posts corporate deck on mutCALR-targeted therapies for myeloproliferative neoplasms](https://longbridge.com/en/news/295448291.md)
- [Analyst Reiterates Buy on Damora Therapeutics, Maintains $45 Price Target on Differentiated Clinical Strategy](https://longbridge.com/en/news/295521208.md)
- [Arcutis Biotherapeutics grants 143,500 RSUs, 37,000 stock options to new hires under inducement plan](https://longbridge.com/en/news/295272046.md)
- [Elkem terminates share option program, cancels 5,017,333 outstanding options](https://longbridge.com/en/news/295490899.md)
- [Faeth Therapeutics grants new-hire stock options for 11,000 shares at $25.5 each](https://longbridge.com/en/news/295272053.md)